Atom Investors LP Jounce Therapeutics, Inc. Transaction History

Atom Investors LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$2.8 - $7.67 $169,523 - $464,372	-60,544 Reduced 84.17%	11,388 $35,000
Q1 2022 May 16, 2022	SELL	$6.01 - $8.54 $28,289 - $40,197	-4,707 Reduced 6.14%	71,932 $488,000
Q4 2021 Feb 14, 2022	BUY	$7.11 - $9.64 $544,903 - $738,799	76,639 New	76,639 $640,000
Q2 2021 Aug 16, 2021	SELL	$6.58 - $10.66 $360,333 - $583,762	-54,762 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$6.73 - $13.87 $368,548 - $759,548	54,762 New	54,762 $562,000

720K

Ticker JNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,694,200
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...

Get notified when there are updates to the investment portfolio of Atom Investors LP, based on Form 13F filings with the SEC.

Stay updated on Atom Investors LP with notifications on news.